BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
Number Citing Articles
1 Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein-Barr Virus-Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies. Cancers (Basel) 2021;13:5189. [PMID: 34680337 DOI: 10.3390/cancers13205189] [Reference Citation Analysis]
2 Yosudjai J, Inpad C, Pothipan P, Saisomboon S, Surangkul D, Phimsen S, Hongsrichan N, Wongkham S, Jirawatnotai S, Roytrakul S, Kaewkong W. Overexpression of AGR2vH, an oncogenic AGR2 spliced transcript, potentiates tumorigenicity and proteomic alterations in cholangiocarcinoma cell. Biosci Biotechnol Biochem 2021;85:2263-73. [PMID: 34494080 DOI: 10.1093/bbb/zbab156] [Reference Citation Analysis]
3 Koustas E, Trifylli EM, Sarantis P, Papavassiliou AG, Karamouzis MV. Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World J Gastrointest Oncol 2021; 13(10): 1229-1243 [PMID: 34721764 DOI: 10.4251/wjgo.v13.i10.1229] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Gil-Hernández A, Arroyo-Campuzano M, Simoni-Nieves A, Zazueta C, Gomez-Quiroz LE, Silva-Palacios A. Relevance of Membrane Contact Sites in Cancer Progression. Front Cell Dev Biol 2020;8:622215. [PMID: 33511135 DOI: 10.3389/fcell.2020.622215] [Reference Citation Analysis]
5 Byrling J, Hilmersson KS, Ansari D, Andersson R, Andersson B. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clin Transl Oncol 2021. [PMID: 34319497 DOI: 10.1007/s12094-021-02685-8] [Reference Citation Analysis]
6 Lang SA, Bednarsch J, Joechle K, Amygdalos I, Czigany Z, Heij L, Ulmer TF, Neumann UP. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Expert Rev Gastroenterol Hepatol 2021;15:497-510. [PMID: 33970740 DOI: 10.1080/17474124.2021.1912591] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Wijetunga I, McVeigh LE, Charalambous A, Antanaviciute A, Carr IM, Nair A, Prasad KR, Ingram N, Coletta PL. Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review. Cancers (Basel) 2020;12:E2817. [PMID: 33007872 DOI: 10.3390/cancers12102817] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, Adeva J, Folseraas T, Fabris L, Macias RIR, Krawczyk M, Krawczyk M, Cardinale V, Braconi C, Alvaro D, Evert M, Banales JM, Valle JW; Group: on behalf of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology 2021;73:2311-25. [PMID: 33073396 DOI: 10.1002/hep.31598] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
9 Vallejo A, Erice O, Entrialgo-Cadierno R, Feliu I, Guruceaga E, Perugorria MJ, Olaizola P, Muggli A, Macaya I, O'Dell M, Ruiz-Fernandez de Cordoba B, Ortiz-Espinosa S, Hezel AF, Arozarena I, Lecanda F, Avila MA, Fernandez-Barrena MG, Evert M, Ponz-Sarvise M, Calvisi DF, Banales JM, Vicent S. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. J Hepatol 2021;75:363-76. [PMID: 33887357 DOI: 10.1016/j.jhep.2021.03.028] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Marsee A, Roos FJM, Verstegen MMA, Gehart H, de Koning E, Lemaigre F, Forbes SJ, Peng WC, Huch M, Takebe T, Vallier L, Clevers H, van der Laan LJW, Spee B; HPB Organoid Consortium. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell 2021;28:816-32. [PMID: 33961769 DOI: 10.1016/j.stem.2021.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tóth M, Wehling L, Thiess L, Rose F, Schmitt J, Weiler SME, Sticht C, De La Torre C, Rausch M, Albrecht T, Grabe N, Duwe L, Andersen JB, Köhler BC, Springfeld C, Mehrabi A, Kulu Y, Schirmacher P, Roessler S, Goeppert B, Breuhahn K. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma. BMC Cancer 2021;21:1079. [PMID: 34615513 DOI: 10.1186/s12885-021-08794-5] [Reference Citation Analysis]
12 Bednarsch J, Czigany Z, Heij LR, Liu D, den Dulk M, Wiltberger G, Bruners P, Ulmer TF, Neumann UP, Lang SA. Compelling Long-Term Results for Liver Resection in Early Cholangiocarcinoma. J Clin Med 2021;10:2959. [PMID: 34209368 DOI: 10.3390/jcm10132959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lomphithak T, Choksi S, Mutirangura A, Tohtong R, Tencomnao T, Usubuchi H, Unno M, Sasano H, Jitkaew S. Receptor-interacting protein kinase 1 is a key mediator in TLR3 ligand and Smac mimetic-induced cell death and suppresses TLR3 ligand-promoted invasion in cholangiocarcinoma. Cell Commun Signal 2020;18:161. [PMID: 33036630 DOI: 10.1186/s12964-020-00661-3] [Reference Citation Analysis]
14 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021; 13(5): 332-350 [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
15 Guardado NV, Llorente K, Blondeau B. Evaluation and Management of Malignant Biliary Obstruction. Surg Oncol Clin N Am 2021;30:491-503. [PMID: 34053664 DOI: 10.1016/j.soc.2021.03.001] [Reference Citation Analysis]
16 Albrecht T, Goeppert B, Brinkmann F, Charbel A, Zhang Q, Schreck J, Wilhelm N, Singer S, Köhler BC, Springfeld C, Mehrabi A, Schirmacher P, Kühl AA, Vogel MN, Jansen H, Utku N, Roessler S. The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. Cancers 2021;13:6272. [DOI: 10.3390/cancers13246272] [Reference Citation Analysis]
17 Klinhom-On N, Seubwai W, Sawanyawisuth K, Lert-Itthiporn W, Waraasawapati S, Detarya M, Wongkham S. FOXM1c is the predominant FOXM1 isoform expressed in cholangiocarcinoma that associated with metastatic potential and poor prognosis of patients. Heliyon 2021;7:e06846. [PMID: 33997388 DOI: 10.1016/j.heliyon.2021.e06846] [Reference Citation Analysis]
18 Vaquero J, Keitel V. Deciphering FAK in intrahepatic cholangiocarcinoma: A novel therapeutic target? J Hepatol 2021:S0168-8278(21)01902-4. [PMID: 34252516 DOI: 10.1016/j.jhep.2021.06.048] [Reference Citation Analysis]
19 Rodrigues MA, Gomes DA, Cosme AL, Sanches MD, Resende V, Cassali GD. Inositol 1,4,5-trisphosphate receptor type 3 (ITPR3) is overexpressed in cholangiocarcinoma and its expression correlates with S100 calcium-binding protein A4 (S100A4). Biomed Pharmacother 2021;145:112403. [PMID: 34798470 DOI: 10.1016/j.biopha.2021.112403] [Reference Citation Analysis]
20 Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 2021;67:103375. [PMID: 33993051 DOI: 10.1016/j.ebiom.2021.103375] [Reference Citation Analysis]
21 Zou W, Wang Z, Zhang X, Xu S, Wang F, Li L, Deng Z, Wang J, Pan K, Ge X, Li C, Liu R, Hu M. PIWIL4 and SUPT5H combine to predict prognosis and immune landscape in intrahepatic cholangiocarcinoma. Cancer Cell Int 2021;21:657. [PMID: 34876138 DOI: 10.1186/s12935-021-02310-2] [Reference Citation Analysis]
22 Marcus R, Ferri-Borgogno S, Hosein A, Foo WC, Ghosh B, Zhao J, Rajapakshe K, Brugarolas J, Maitra A, Gupta S. Oncogenic KRAS Requires Complete Loss of BAP1 Function for Development of Murine Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:5709. [PMID: 34830866 DOI: 10.3390/cancers13225709] [Reference Citation Analysis]
23 De B, Abu-Gheida I, Patel A, Ng SSW, Zaid M, Thunshelle CP, Elganainy D, Corrigan KL, Rooney MK, Javle M, Raghav K, Lee SS, Vauthey JN, Tzeng CD, Tran Cao HS, Ludmir EB, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Koay EJ. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med 2021;11:1270. [PMID: 34945742 DOI: 10.3390/jpm11121270] [Reference Citation Analysis]
24 Cousin S, Cantarel C, Guegan JP, Mazard T, Gomez-Roca C, Metges JP, Bellera C, Adenis A, Korakis I, Poureau PG, Bourcier K, Toulmonde M, Kind M, Rey C, Auzanneau C, Bessede A, Soubeyran I, Italiano A. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer 2022;162:161-9. [PMID: 34998048 DOI: 10.1016/j.ejca.2021.11.012] [Reference Citation Analysis]
25 Huang X, Fan M, Huang W. Pleiotropic roles of FXR in liver and colorectal cancers. Mol Cell Endocrinol 2022;543:111543. [PMID: 34995680 DOI: 10.1016/j.mce.2021.111543] [Reference Citation Analysis]
26 Truong SDA, Tummanatsakun D, Proungvitaya T, Limpaiboon T, Wongwattanakul M, Chua-On D, Roytrakul S, Proungvitaya S. Serum Levels of Cytokine-Induced Apoptosis Inhibitor 1 (CIAPIN1) as a Potential Prognostic Biomarker of Cholangiocarcinoma. Diagnostics (Basel) 2021;11:1054. [PMID: 34201138 DOI: 10.3390/diagnostics11061054] [Reference Citation Analysis]
27 Liu Y, Li G, Lu Z, Wang T, Yang Y, Wang X, Liu J. Effect of vascular resection for perihilar cholangiocarcinoma: a systematic review and meta-analysis. PeerJ 2021;9:e12184. [PMID: 34631316 DOI: 10.7717/peerj.12184] [Reference Citation Analysis]
28 Merdrignac A, Papoutsoglou P, Coulouarn C. Long Noncoding RNAs in Cholangiocarcinoma. Hepatology 2021;73:1213-26. [PMID: 32865244 DOI: 10.1002/hep.31534] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Pangestu NS, Chueakwon P, Talabnin K, Khiaowichit J, Talabnin C. RNF43 overexpression attenuates the Wnt/β-catenin signalling pathway to suppress tumour progression in cholangiocarcinoma. Oncol Lett 2021;22:846. [PMID: 34733364 DOI: 10.3892/ol.2021.13107] [Reference Citation Analysis]
30 Tantau AI, Mandrutiu A, Pop A, Zaharie RD, Crisan D, Preda CM, Tantau M, Mercea V. Extrahepatic cholangiocarcinoma: Current status of endoscopic approach and additional therapies. World J Hepatol 2021; 13(2): 166-186 [PMID: 33708349 DOI: 10.4254/wjh.v13.i2.166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
31 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Reference Citation Analysis]
32 Mancinelli R, Cutone A, Rosa L, Lepanto MS, Onori P, Pannarale L, Franchitto A, Gaudio E, Valenti P. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma. Eur J Histochem 2020;64. [PMID: 33131269 DOI: 10.4081/ejh.2020.3156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Sawanyawisuth K, Sashida G, Sheng G. Epithelial-Mesenchymal Transition in Liver Fluke-Induced Cholangiocarcinoma. Cancers (Basel) 2021;13:791. [PMID: 33672838 DOI: 10.3390/cancers13040791] [Reference Citation Analysis]
34 Matsuda T, Umeda Y, Matsuda T, Endo Y, Sato D, Kojima T, Sui K, Inagaki M, Ota T, Hioki M, Oishi M, Kimura M, Murata T, Ishido N, Yagi T, Fujiwara T. Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:708. [PMID: 34130648 DOI: 10.1186/s12885-021-08424-0] [Reference Citation Analysis]
35 Sipra QUAR, Shroff R. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opinion on Investigational Drugs 2021;30:281-4. [DOI: 10.1080/13543784.2021.1849139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
36 Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol 2021;5:PO. [PMID: 34778691 DOI: 10.1200/PO.21.00064] [Reference Citation Analysis]
37 Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, Castro RE, González-Gallego J, Mauriz JL, Marin JJG. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging (Albany NY) 2021;13:23416-34. [PMID: 34633987 DOI: 10.18632/aging.203620] [Reference Citation Analysis]
38 Han SY, Park SH, Ko HS, Jang A, Seo HI, Lee SJ, Kim GH, Kim DU. Vimentin-Positive Circulating Tumor Cells as Diagnostic and Prognostic Biomarkers in Patients with Biliary Tract Cancer. J Clin Med 2021;10:4435. [PMID: 34640452 DOI: 10.3390/jcm10194435] [Reference Citation Analysis]
39 Okusaka T. Cholangiocarcinoma: is it time for a revolution? Expert Rev Gastroenterol Hepatol 2021;15:467-70. [PMID: 33840344 DOI: 10.1080/17474124.2021.1915766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Thuehøj AU, Andersen NC, Worm ES, Høyer M, Tabaksblat EM, Weber B, Mortensen HR. Clinical outcomes after stereotactic ablative radiotherapy in locally advanced cholangiocarcinoma. Acta Oncol 2021;:1-5. [PMID: 34726565 DOI: 10.1080/0284186X.2021.1995893] [Reference Citation Analysis]
41 Nikas IP, Mountzios G, Sydney GI, Ioakim KJ, Won J, Papageorgis P. Evaluating Pancreatic and Biliary Neoplasms with Small Biopsy-Based Next Generation Sequencing (NGS): Doing More with Less. Cancers 2022;14:397. [DOI: 10.3390/cancers14020397] [Reference Citation Analysis]
42 Raggi C, Taddei ML, Sacco E, Navari N, Correnti M, Piombanti B, Pastore M, Campani C, Pranzini E, Iorio J, Lori G, Lottini T, Peano C, Cibella J, Lewinska M, Andersen JB, di Tommaso L, Viganò L, Di Maira G, Madiai S, Ramazzotti M, Orlandi I, Arcangeli A, Chiarugi P, Marra F. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol 2021;74:1373-85. [PMID: 33484774 DOI: 10.1016/j.jhep.2020.12.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Ju X, Tang Y, Qu R, Hao S. The Emerging Role of Circ-SHPRH in Cancer. Onco Targets Ther 2021;14:4177-88. [PMID: 34285509 DOI: 10.2147/OTT.S317403] [Reference Citation Analysis]
44 Thornblade LW, Wong P, Li D, Warner SG, Chang S, Raoof M, Kessler J, Amini A, Lin J, Chung V, Singh G, Fong Y, Melstrom LG. Patterns of Whole Exome Sequencing in Resected Cholangiocarcinoma. Cancers (Basel) 2021;13:4062. [PMID: 34439216 DOI: 10.3390/cancers13164062] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Di Matteo S, Nevi L, Overi D, Landolina N, Faccioli J, Giulitti F, Napoletano C, Oddi A, Marziani AM, Costantini D, De Rose AM, Melandro F, Bragazzi MC, Grazi GL, Berloco PB, Giuliante F, Donato G, Moretta L, Carpino G, Cardinale V, Gaudio E, Alvaro D. Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Sci Rep 2021;11:2557. [PMID: 33510179 DOI: 10.1038/s41598-021-81172-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
46 Dwyer BJ, Jarman EJ, Gogoi-Tiwari J, Ferreira-Gonzalez S, Boulter L, Guest RV, Kendall TJ, Kurian D, Kilpatrick AM, Robson AJ, O'Duibhir E, Man TY, Campana L, Starkey Lewis PJ, Wigmore SJ, Olynyk JK, Ramm GA, Tirnitz-Parker JEE, Forbes SJ. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. J Hepatol 2021;74:860-72. [PMID: 33221352 DOI: 10.1016/j.jhep.2020.11.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Keenan BP, Kelley RKK. Key challenges for drugs in clinical development for cholangiocarcinoma. Expert Opin Investig Drugs 2021;30:285-90. [PMID: 33530767 DOI: 10.1080/13543784.2021.1880565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Louis C, Edeline J, Coulouarn C. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Ther Targets 2021;25:153-62. [PMID: 33502260 DOI: 10.1080/14728222.2021.1882998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Han S, Lee SY, Wang WW, Tan YB, Sim RHZ, Cheong R, Tan C, Hopkins R, Connolly J, Shuen WH, Toh HC. A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs). Cancers (Basel) 2020;12:E3404. [PMID: 33212880 DOI: 10.3390/cancers12113404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Gonçalves JPL, Bollwein C, Schlitter AM, Martin B, Märkl B, Utpatel K, Weichert W, Schwamborn K. The Impact of Histological Annotations for Accurate Tissue Classification Using Mass Spectrometry Imaging. Metabolites 2021;11:752. [PMID: 34822410 DOI: 10.3390/metabo11110752] [Reference Citation Analysis]
51 Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. JAMA Oncol 2021;7:1669-77. [PMID: 34554208 DOI: 10.1001/jamaoncol.2021.3836] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Klufah F, Mobaraki G, Chteinberg E, Alharbi RA, Winnepenninckx V, Speel EJM, Rennspiess D, Olde Damink SW, Neumann UP, Kurz AK, Samarska I, Zur Hausen A. High Prevalence of Human Polyomavirus 7 in Cholangiocarcinomas and Adjacent Peritumoral Hepatocytes: Preliminary Findings. Microorganisms 2020;8:E1125. [PMID: 32726909 DOI: 10.3390/microorganisms8081125] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
53 Sato K, Zhang W, Safarikia S, Isidan A, Chen AM, Li P, Francis H, Kennedy L, Baiocchi L, Alvaro D, Glaser S, Ekser B, Alpini G. Organoids and Spheroids as Models for Studying Cholestatic Liver Injury and Cholangiocarcinoma. Hepatology 2021;74:491-502. [PMID: 33222247 DOI: 10.1002/hep.31653] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Ahn CS, Kim JG, Kang I, Kong Y. Omega-Class Glutathione Transferases of Carcinogenic Liver Fluke, Clonorchis sinensis, Modulate Apoptosis and Differentiation of Host Cholangiocytes. Antioxidants (Basel) 2021;10:1017. [PMID: 34202740 DOI: 10.3390/antiox10071017] [Reference Citation Analysis]
55 Vignone A, Biancaniello F, Casadio M, Pesci L, Cardinale V, Ridola L, Alvaro D. Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review. J Clin Med 2021;10:4901. [PMID: 34768421 DOI: 10.3390/jcm10214901] [Reference Citation Analysis]
56 Beetz O, Timrott A, Weigle CA, Schroeter A, Cammann S, Klempnauer J, Vondran FWR, Oldhafer F. Proposal of a New Definition of "Very Early" Intrahepatic Cholangiocarcinoma-A Retrospective Single-Center Analysis. J Clin Med 2021;10:4073. [PMID: 34575181 DOI: 10.3390/jcm10184073] [Reference Citation Analysis]
57 Li H, Qu L, Zhang H, Liu J, Zhang X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci Rep 2021;11:13713. [PMID: 34211100 DOI: 10.1038/s41598-021-93250-4] [Reference Citation Analysis]
58 Rizzo A. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer. Cancer Treat Res Commun 2021;27:100360. [PMID: 33799005 DOI: 10.1016/j.ctarc.2021.100360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Reference Citation Analysis]
60 Lleo A, Colapietro F, Maisonneuve P, Aloise M, Craviotto V, Ceriani R, Rimassa L, Badalamenti S, Donadon M, Pedicini V, Repici A, Di Tommaso L, Voza A, Torzilli G, Aghemo A. Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. Cancers (Basel) 2021;13:2070. [PMID: 33922972 DOI: 10.3390/cancers13092070] [Reference Citation Analysis]
61 Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals (Basel) 2021;14:51. [PMID: 33440754 DOI: 10.3390/ph14010051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3661. [PMID: 34359564 DOI: 10.3390/cancers13153661] [Reference Citation Analysis]
63 Rizzo A, Federico AD, Ricci AD, Frega G, Palloni A, Pagani R, Tavolari S, Marco MD, Brandi G. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. Cancer Control 2020;27:1073274820983013. [PMID: 33356500 DOI: 10.1177/1073274820983013] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Gao Z, Wang J, Shen S, Bo X, Suo T, Ni X, Liu H, Huang L, Liu H. The impact of preoperative biliary drainage on postoperative outcomes in patients with malignant obstructive jaundice: a retrospective analysis of 290 consecutive cases at a single medical center. World J Surg Oncol 2022;20:7. [PMID: 34991594 DOI: 10.1186/s12957-021-02476-z] [Reference Citation Analysis]
65 Loilome W, Dokduang H, Suksawat M, Padthaisong S. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma. Expert Opin Investig Drugs 2021;:1-22. [PMID: 34292795 DOI: 10.1080/13543784.2021.1955102] [Reference Citation Analysis]
66 Ghidini M, Ramai D, Facciorusso A, Singh J, Tai W, Rijavec E, Galassi B, Grossi F, Indini A. Metabolic disorders and the risk of cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:999-1007. [PMID: 34423721 DOI: 10.1080/17474124.2021.1946393] [Reference Citation Analysis]
67 Gruttadauria S, Barbera F, Pagano D, Liotta R, Miraglia R, Barbara M, Bavetta MG, Cammà C, Petridis I, Di Carlo D, Conaldi PG, Di Francesco F. Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling. Cancers (Basel) 2021;13:6049. [PMID: 34885159 DOI: 10.3390/cancers13236049] [Reference Citation Analysis]
68 Ding GY, Ma JQ, Yun JP, Chen X, Ling Y, Zhang S, Shi JY, Chang YQ, Ji Y, Wang XY, Tan WM, Yuan KF, Yan B, Zhang XM, Liang F, Zhou J, Fan J, Zeng Y, Cai MY, Gao Q. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol 2021:S0168-8278(21)02178-4. [PMID: 34793865 DOI: 10.1016/j.jhep.2021.10.030] [Reference Citation Analysis]
69 Saffioti F, Mavroeidis VK. Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis. World J Gastrointest Oncol 2021; 13(10): 1336-1366 [PMID: 34721770 DOI: 10.4251/wjgo.v13.i10.1336] [Reference Citation Analysis]
70 Yoon SB, Moon SH, Ko SW, Lim H, Kang HS, Kim JH. Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-Analysis. Dig Dis Sci 2021. [PMID: 34263382 DOI: 10.1007/s10620-021-07138-4] [Reference Citation Analysis]
71 Wu CE, Yeh CN. Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial. Biomolecules 2021;11:1626. [PMID: 34827625 DOI: 10.3390/biom11111626] [Reference Citation Analysis]
72 Wang H, Song X, Liao H, Wang P, Zhang Y, Che L, Zhang J, Zhou Y, Cigliano A, Ament C, Superville D, Ribback S, Reeves M, Pes GM, Liang B, Wu H, Evert M, Calvisi DF, Zeng Y, Chen X. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans. Hepatology 2021;74:248-63. [PMID: 33368437 DOI: 10.1002/hep.31692] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
73 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
74 Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer 2021. [PMID: 34309846 DOI: 10.1002/ijc.33751] [Reference Citation Analysis]
75 Boottanun P, Ino Y, Shimada K, Hiraoka N, Angata K, Narimatsu H. Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma. Oncol Lett 2021;22:760. [PMID: 34539864 DOI: 10.3892/ol.2021.13021] [Reference Citation Analysis]
76 Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med 2021;10:2552. [PMID: 34207700 DOI: 10.3390/jcm10122552] [Reference Citation Analysis]
77 Correnti M, Cappon A, Pastore M, Piombanti B, Lori G, Oliveira DVPN, Munoz-Garrido P, Lewinska M, Andersen JB, Coulouarn C, Sulpice L, Peraldo Neia C, Cavalloni G, Quarta S, Biasiolo A, Fassan M, Ramazzotti M, Parri M, Recalcati S, di Tommaso L, Campani C, Invernizzi P, Torzilli G, Marra F, Pontisso P, Raggi C. The protease-inhibitor SerpinB3 as a critical modulator of the stem-like subset in human cholangiocarcinoma. Liver Int 2021. [PMID: 34478594 DOI: 10.1111/liv.15049] [Reference Citation Analysis]
78 Li X, Yang ZS, Cai WW, Deng Y, Chen L, Tan SL. Dihydromyricetin Inhibits Tumor Growth and Epithelial-Mesenchymal Transition through regulating miR-455-3p in Cholangiocarcinoma. J Cancer 2021;12:6058-70. [PMID: 34539879 DOI: 10.7150/jca.61311] [Reference Citation Analysis]
79 Chen X, Rong D, Zhang L, Ni C, Han G, Lu Y, Chen X, Gao Y, Wang X. Evaluation of nodal status in intrahepatic cholangiocarcinoma: a population-based study. Ann Transl Med 2021;9:1359. [PMID: 34733911 DOI: 10.21037/atm-21-2785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun 2021;27:100354. [PMID: 33756174 DOI: 10.1016/j.ctarc.2021.100354] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
82 Vogel A, Saborowski A. Current and Future Systemic Therapies in Biliary Tract Cancer. Visc Med 2021;37:32-8. [PMID: 33708816 DOI: 10.1159/000513969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Sato K, Baiocchi L, Kennedy L, Zhang W, Ekser B, Glaser S, Francis H, Alpini G. Current Advances in Basic and Translational Research of Cholangiocarcinoma. Cancers (Basel) 2021;13:3307. [PMID: 34282753 DOI: 10.3390/cancers13133307] [Reference Citation Analysis]
84 Rizzo A, Brandi G. TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. Cancer Treat Res Commun 2021;27:100351. [PMID: 33752169 DOI: 10.1016/j.ctarc.2021.100351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
85 Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2368. [PMID: 34072277 DOI: 10.3390/jcm10112368] [Reference Citation Analysis]
86 Qian M, Yan F, Wang W, Du J, Yuan T, Wu R, Zhao C, Wang J, Lu J, Zhang B, Lin N, Dong X, Dai X, Dong X, Yang B, Zhu H, He Q. Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression. Acta Pharmaceutica Sinica B 2021;11:4008-19. [DOI: 10.1016/j.apsb.2021.04.003] [Reference Citation Analysis]
87 Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X, Decker A, Worley J, Caviglia JM, Yu L, Yin D, Saito Y, Savage T, Wells RG, Mack M, Zender L, Arpaia N, Remotti HE, Rabadan R, Sims P, Leblond AL, Weber A, Riener MO, Stockwell BR, Gaublomme J, Llovet JM, Kalluri R, Michalopoulos GK, Seki E, Sia D, Chen X, Califano A, Schwabe RF. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 2021;39:866-882.e11. [PMID: 33930309 DOI: 10.1016/j.ccell.2021.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
88 Fragkou N, Sideras L, Panas P, Emmanouilides C, Sinakos E. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence? World J Gastroenterol 2021; 27(27): 4252-4275 [PMID: 34366604 DOI: 10.3748/wjg.v27.i27.4252] [Reference Citation Analysis]
89 Zhang R, Li Q, Fu J, Jin Z, Su J, Zhang J, Chen C, Geng Z, Zhang D. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:112. [PMID: 33535978 DOI: 10.1186/s12885-021-07788-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Czauderna C, Kirstein MM, Tews HC, Vogel A, Marquardt JU. Molecular Subtypes and Precision Oncology in Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2803. [PMID: 34202401 DOI: 10.3390/jcm10132803] [Reference Citation Analysis]
91 Rao B, Ren T, Wang X, Wang H, Zou Y, Sun Y, Liu S, Ren Z, Yu Z. Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Front Physiol 2021;12:715536. [PMID: 34867436 DOI: 10.3389/fphys.2021.715536] [Reference Citation Analysis]
92 Marin JJG, Sanchon-Sanchez P, Cives-Losada C, Del Carmen S, González-Santiago JM, Monte MJ, Macias RIR. Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance. Cancers (Basel) 2021;13:2358. [PMID: 34068398 DOI: 10.3390/cancers13102358] [Reference Citation Analysis]
93 Rizzo A, Ricci AD, Brandi G. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 2021;27:100337. [PMID: 33611090 DOI: 10.1016/j.ctarc.2021.100337] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
94 Bednarsch J, Kather J, Tan X, Sivakumar S, Cacchi C, Wiltberger G, Czigany Z, Ulmer F, Neumann UP, Heij LR. Nerve Fibers in the Tumor Microenvironment as a Novel Biomarker for Oncological Outcome in Patients Undergoing Surgery for Perihilar Cholangiocarcinoma. Liver Cancer 2021;10:260-74. [PMID: 34239812 DOI: 10.1159/000515303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Personeni N, Lleo A, Pressiani T, Colapietro F, Openshaw MR, Stavraka C, Pouptsis A, Pinato DJ, Rimassa L. Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options. Cancers (Basel) 2020;12:E3370. [PMID: 33202975 DOI: 10.3390/cancers12113370] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
96 Yao Y, Jiao D, Liu Z, Chen J, Zhou X, Li Z, Li J, Han X. Novel miRNA Predicts Survival and Prognosis of Cholangiocarcinoma Based on RNA-seq Data and In Vitro Experiments. Biomed Res Int 2020;2020:5976127. [PMID: 33490245 DOI: 10.1155/2020/5976127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treatment Reviews 2021;95:102170. [DOI: 10.1016/j.ctrv.2021.102170] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
98 Balasubramanian B, Venkatraman S, Janvilisri T, Suthiphongchai T, Jitkaew S, Sripa J, Tohtong R. RTK25: A Comprehensive Molecular Profiling Strategy in Cholangiocarcinoma Using an Integrated Bioinformatics Approach. Pharmaceuticals (Basel) 2021;14:898. [PMID: 34577598 DOI: 10.3390/ph14090898] [Reference Citation Analysis]
99 Muñoz-Martínez S, Forner A. The tireless search to improve the prognostic assessment of intrahepatic cholangiocarcinoma: An urgent need. Liver Int 2021;41:252-4. [PMID: 33464725 DOI: 10.1111/liv.14768] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
101 Boilève A, Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs 2021;30:401-9. [PMID: 33641556 DOI: 10.1080/13543784.2021.1896703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Neureiter D, Mayr C, Kiesslich T. The challenges of combinatory immunotherapy for biliary tract cancer. Expert Opin Investig Drugs 2021;30:591-4. [PMID: 33874822 DOI: 10.1080/13543784.2021.1916467] [Reference Citation Analysis]
103 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022. [PMID: 34982503 DOI: 10.1111/liv.15152] [Reference Citation Analysis]
104 Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open 2022;7:100378. [PMID: 35032765 DOI: 10.1016/j.esmoop.2021.100378] [Reference Citation Analysis]
105 Roberts HJ, Wo JY. Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox. Cancer 2021. [PMID: 34847255 DOI: 10.1002/cncr.34033] [Reference Citation Analysis]
106 Gao Y, Zhou R, Huang JF, Hu B, Cheng JW, Huang XW, Wang PX, Peng HX, Guo W, Zhou J, Fan J, Yang XR. Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. Front Oncol 2021;11:704042. [PMID: 34327143 DOI: 10.3389/fonc.2021.704042] [Reference Citation Analysis]
107 Zhang G, Liu X, Sun Z, Feng X, Wang H, Hao J, Zhang X. A2M is a potential core gene in intrahepatic cholangiocarcinoma. BMC Cancer 2022;22:5. [PMID: 34979994 DOI: 10.1186/s12885-021-09070-2] [Reference Citation Analysis]
108 Paillet J, Plantureux C, Lévesque S, Le Naour J, Stoll G, Sauvat A, Caudana P, Tosello Boari J, Bloy N, Lachkar S, Martins I, Opolon P, Checcoli A, Delaune A, Robil N, de la Grange P, Hamroune J, Letourneur F, Autret G, Leung PSC, Gershwin ME, Zhu JS, Kurth MJ, Lekbaby B, Augustin J, Kim Y, Gujar S, Coulouarn C, Fouassier L, Zitvogel L, Piaggio E, Housset C, Soussan P, Maiuri MC, Kroemer G, Pol JG. Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma. J Exp Med 2021;218:e20200853. [PMID: 34495298 DOI: 10.1084/jem.20200853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Wang X, Lee J, Xie C. Autophagy Regulation on Cancer Stem Cell Maintenance, Metastasis, and Therapy Resistance. Cancers 2022;14:381. [DOI: 10.3390/cancers14020381] [Reference Citation Analysis]
110 Ding Y, Han X, Sun Z, Tang J, Wu Y, Wang W. Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. Front Oncol 2021;11:691380. [PMID: 34527576 DOI: 10.3389/fonc.2021.691380] [Reference Citation Analysis]
111 Park HJ, Park B, Park SY, Choi SH, Rhee H, Park JH, Cho ES, Yeom SK, Park S, Park MS, Lee SS. Preoperative prediction of postsurgical outcomes in mass-forming intrahepatic cholangiocarcinoma based on clinical, radiologic, and radiomics features. Eur Radiol 2021. [PMID: 33890153 DOI: 10.1007/s00330-021-07926-6] [Reference Citation Analysis]
112 Rizzo A, Brandi G. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. Cancer Treat Res Commun 2021;27:100334. [PMID: 33592563 DOI: 10.1016/j.ctarc.2021.100334] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opinion on Investigational Drugs 2021;30:317-24. [DOI: 10.1080/13543784.2021.1837774] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
114 Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets 2021;25:835-45. [PMID: 34806500 DOI: 10.1080/14728222.2021.2010046] [Reference Citation Analysis]
115 Li Q, Che F, Wei Y, Jiang HY, Zhang Y, Song B. Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Rev Gastroenterol Hepatol 2021;15:1267-79. [PMID: 34452581 DOI: 10.1080/17474124.2021.1974294] [Reference Citation Analysis]
116 Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S. Non-surgical treatment of hilar cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(11): 1696-1708 [PMID: 34853644 DOI: 10.4251/wjgo.v13.i11.1696] [Reference Citation Analysis]
117 Izquierdo-Sanchez L, Banales JM, Rodrigues PM. A look back at cholangiocarcinoma in Finland. United European Gastroenterol J 2021. [PMID: 34581503 DOI: 10.1002/ueg2.12157] [Reference Citation Analysis]
118 Yoo C, Shin SH, Park JO, Kim KP, Jeong JH, Ryoo BY, Lee W, Song KB, Hwang DW, Park JH, Lee JH. Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. Cancers (Basel) 2021;13:1647. [PMID: 33916008 DOI: 10.3390/cancers13071647] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
119 Fung BM, Tabibian JH. Primary sclerosing cholangitis-associated cholangiocarcinoma: special considerations and best practices. Expert Rev Gastroenterol Hepatol 2021;15:487-96. [PMID: 33682586 DOI: 10.1080/17474124.2021.1900732] [Reference Citation Analysis]
120 Zhou SL, Xin HY, Sun RQ, Zhou ZJ, Hu ZQ, Luo CB, Wang PC, Li J, Fan J, Zhou J. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. JAMA Surg 2021. [PMID: 34730772 DOI: 10.1001/jamasurg.2021.5679] [Reference Citation Analysis]
121 Wintachai P, Lim JQ, Techasen A, Lert-Itthiporn W, Kongpetch S, Loilome W, Chindaprasirt J, Titapun A, Namwat N, Khuntikeo N, Jusakul A. Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma. Diagnostics (Basel) 2021;11:999. [PMID: 34070951 DOI: 10.3390/diagnostics11060999] [Reference Citation Analysis]
122 Marin JJ, Macias RI. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opin Investig Drugs 2021;30:675-9. [PMID: 33934687 DOI: 10.1080/13543784.2021.1916912] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
123 Roy S, Banerjee P, Ekser B, Bayless K, Zawieja D, Alpini G, Glaser SS, Chakraborty S. Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer. Am J Pathol 2021;191:2052-63. [PMID: 34509441 DOI: 10.1016/j.ajpath.2021.08.011] [Reference Citation Analysis]
124 Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 2021;13:1113-34. [PMID: 34190581 DOI: 10.2217/imt-2021-0126] [Reference Citation Analysis]
125 Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M. Cholangiocarcinoma. Pathologica 2021;113:158-69. [PMID: 34294934 DOI: 10.32074/1591-951X-252] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Dana P, Kariya R, Lert-Itthiporn W, Seubwai W, Saisomboon S, Wongkham C, Okada S, Wongkham S, Vaeteewoottacharn K. Homophilic Interaction of CD147 Promotes IL-6-Mediated Cholangiocarcinoma Invasion via the NF-κB-Dependent Pathway. Int J Mol Sci 2021;22:13496. [PMID: 34948304 DOI: 10.3390/ijms222413496] [Reference Citation Analysis]
127 Zou W, Wang Z, Wang F, Li L, Liu R, Hu M. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:608. [PMID: 34034689 DOI: 10.1186/s12885-021-08322-5] [Reference Citation Analysis]
128 Ney A, Garcia-Sampedro A, Goodchild G, Acedo P, Fusai G, Pereira SP. Biliary Strictures and Cholangiocarcinoma - Untangling a Diagnostic Conundrum. Front Oncol 2021;11:699401. [PMID: 34660269 DOI: 10.3389/fonc.2021.699401] [Reference Citation Analysis]
129 Yang Y, Zou X, Zhou W, Yuan G, Hu D, Kuang D, Shen Y, Xie Q, Zhang Q, Hu X, Li Z. Multiparametric MRI-Based Radiomic Signature for Preoperative Evaluation of Overall Survival in Intrahepatic Cholangiocarcinoma After Partial Hepatectomy. J Magn Reson Imaging 2022. [PMID: 35049076 DOI: 10.1002/jmri.28071] [Reference Citation Analysis]
130 Carbone M, Baiocchi L. Management of cholangiocarcinoma in the third millennium: time to be guided! Dig Liver Dis 2020;52:1428-9. [PMID: 33248542 DOI: 10.1016/j.dld.2020.11.003] [Reference Citation Analysis]
131 Hao J, Deng H, Yang Y, Chen L, Wu Q, Yao P, Li J, Li B, Jin X, Wang H, Duan H. Downregulation of MCM8 expression restrains the malignant progression of cholangiocarcinoma. Oncol Rep 2021;46:235. [PMID: 34523691 DOI: 10.3892/or.2021.8186] [Reference Citation Analysis]
132 Wu H, Wei Y, Jian M, Lu H, Song Q, Hao L, Yue Y. Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma. Onco Targets Ther 2021;14:39-51. [PMID: 33442265 DOI: 10.2147/OTT.S288982] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Uson Junior PLS, Arora M, Bogenberger JM, Borad MJ. Recent advances in understanding cholangiocarcinoma. Fac Rev 2020;9:15. [PMID: 33659947 DOI: 10.12703/b/9-15] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Song J, Cui D, Wang J, Qin J, Wang S, Wang Z, Zhai X, Ma H, Ma D, Liu Y, Jin B, Liu Z. Overexpression of HMGA1 confers radioresistance by transactivating RAD51 in cholangiocarcinoma. Cell Death Discov 2021;7:322. [PMID: 34716319 DOI: 10.1038/s41420-021-00721-8] [Reference Citation Analysis]
135 Panayotova G, Guerra J, Guarrera JV, Lunsford KE. The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2428. [PMID: 34070772 DOI: 10.3390/jcm10112428] [Reference Citation Analysis]
136 Anichini G, Carrassa L, Stecca B, Marra F, Raggi C. The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers (Basel) 2021;13:4774. [PMID: 34638259 DOI: 10.3390/cancers13194774] [Reference Citation Analysis]
137 Louis C, Coulouarn C. One stone, two birds: circACTN4, a nexus for a coordinated activation of Hippo and Wnt/β-catenin pathways in cholangiocarcinoma. J Hepatol 2021:S0168-8278(21)02108-5. [PMID: 34653593 DOI: 10.1016/j.jhep.2021.10.002] [Reference Citation Analysis]
138 Di Federico A, Rizzo A, Ricci AD, Frega G, Palloni A, Tavolari S, Brandi G. Nivolumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:325-32. [PMID: 33307866 DOI: 10.1080/13543784.2021.1863946] [Reference Citation Analysis]
139 Rizzo A, Ricci AD, Bonucci C, Tober N, Palloni A, Frega G, Brandi G. Experimental HER2- targeted therapies for biliary tract cancer. Expert Opin Investig Drugs 2021;30:389-99. [PMID: 33218269 DOI: 10.1080/13543784.2021.1854724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
140 Mayr C, Kiesslich T, Erber S, Bekric D, Dobias H, Beyreis M, Ritter M, Jäger T, Neumayer B, Winkelmann P, Klieser E, Neureiter D. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers (Basel) 2021;13:3862. [PMID: 34359763 DOI: 10.3390/cancers13153862] [Reference Citation Analysis]
141 Wang Y, Chen T, Li K, Mu W, Liu Z, Shi A, Liu J, Zhao W, Lian S, Huang S, Pan C, Zhang Z. Recent Advances in the Mechanism Research and Clinical Treatment of Anti-Angiogenesis in Biliary Tract Cancer. Front Oncol 2021;11:777617. [PMID: 34778094 DOI: 10.3389/fonc.2021.777617] [Reference Citation Analysis]
142 Nara S, Esaki M, Ban D, Takamoto T, Mizui T, Shimada K. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:537-45. [PMID: 33793366 DOI: 10.1080/17474124.2021.1911645] [Reference Citation Analysis]
143 Kim YY, Yeom SK, Shin H, Choi SH, Rhee H, Park JH, Cho ES, Park S, Lee SS, Park MS. Clinical Staging of Mass-Forming Intrahepatic Cholangiocarcinoma: Computed Tomography Versus Magnetic Resonance Imaging. Hepatol Commun 2021;5:2009-18. [PMID: 34559470 DOI: 10.1002/hep4.1774] [Reference Citation Analysis]
144 Pol JG, Paillet J, Plantureux C, Kroemer G. Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma. Oncoimmunology 2021;10:1968595. [PMID: 34527429 DOI: 10.1080/2162402X.2021.1968595] [Reference Citation Analysis]
145 Cloyd JM, Pawlik TM. Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. Hepatobiliary Surg Nutr 2021;10:515-7. [PMID: 34430532 DOI: 10.21037/hbsn-2021-12] [Reference Citation Analysis]
146 Zane KE, Cloyd JM, Mumtaz KS, Wadhwa V, Makary MS. Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World J Clin Oncol 2021; 12(9): 725-745 [PMID: 34631439 DOI: 10.5306/wjco.v12.i9.725] [Reference Citation Analysis]
147 Izumiya M, Kato S, Hippo Y. Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice. Cancers (Basel) 2021;13:2292. [PMID: 34064809 DOI: 10.3390/cancers13102292] [Reference Citation Analysis]
148 Xue W, Dong B, Zhao Y, Wang Y, Yang C, Xie Y, Niu Z, Zhu C. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma. Cell Oncol (Dordr) 2021;44:1351-61. [PMID: 34796468 DOI: 10.1007/s13402-021-00642-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Review of Gastroenterology & Hepatology 2021;15:483-5. [DOI: 10.1080/17474124.2021.1864325] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
150 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Huang P, Zhou Y, Chen Y. Significant Response to Camrelizumab Plus Targeted Drugs in Recurrent Intrahepatic Cholangiocarcinoma: a Case Report and Literature Review. J Gastrointest Cancer 2021. [PMID: 34312770 DOI: 10.1007/s12029-021-00637-7] [Reference Citation Analysis]
152 Hao WY, Guo LW, Luo J, Shao GL, Zheng JP. LncRNA TUG1 Promotes Growth and Metastasis of Cholangiocarcinoma Cells by Inhibiting miR-29a. Cancer Manag Res 2020;12:11103-11. [PMID: 33173343 DOI: 10.2147/CMAR.S270515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Casadio M, Biancaniello F, Overi D, Venere R, Carpino G, Gaudio E, Alvaro D, Cardinale V. Molecular Landscape and Therapeutic Strategies in Cholangiocarcinoma: An Integrated Translational Approach towards Precision Medicine. Int J Mol Sci 2021;22:5613. [PMID: 34070643 DOI: 10.3390/ijms22115613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Soares KC, Jarnagin WR. The Landmark Series: Hilar Cholangiocarcinoma. Ann Surg Oncol 2021;28:4158-70. [PMID: 33829358 DOI: 10.1245/s10434-021-09871-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
155 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
156 Shi T, Morishita A, Kobara H, Masaki T. The Role of microRNAs in Cholangiocarcinoma. Int J Mol Sci 2021;22:7627. [PMID: 34299246 DOI: 10.3390/ijms22147627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
157 Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, Waldschmidt DT, Goyal L, Borbath I, El-Khoueiry A, Borad MJ, Yong WP, Philip PA, Bitzer M, Tanasanvimon S, Li A, Pande A, Soifer HS, Shepherd SP, Moran S, Zhu AX, Bekaii-Saab TS, Abou-Alfa GK. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00196-5. [PMID: 34358484 DOI: 10.1016/S2468-1253(21)00196-5] [Reference Citation Analysis]
158 Lücke J, Sabihi M, Zhang T, Bauditz LF, Shiri AM, Giannou AD, Huber S. The good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies. Semin Immunopathol 2021. [PMID: 33851257 DOI: 10.1007/s00281-021-00854-z] [Reference Citation Analysis]
159 Wu R, Zhang Y, Cheng Q, Wu J, Zhu Y, Shi X, Qiu X, Yang S, Wang S, Zheng B, Wu T, Li Z, Wang K, Zhang Y, Zhao Y, Wang W, Bao J, Hu J, Wu X, Wang H, Jiang X, Chen L. The effect of biliary obstruction, biliary drainage and bile reinfusion on bile acid metabolism and gut microbiota in mice. Liver Int 2021. [PMID: 34459095 DOI: 10.1111/liv.15047] [Reference Citation Analysis]
160 Yang JD, Ghoz H, Aboelsoud MM, Taylor WR, Yab TC, Berger CK, Cao X, Foote PH, Giama NH, Barr Fritcher EG, Mahoney DW, Moser CD, Smyrk TC, Kipp BR, Gores GJ, Roberts LR, Kisiel JB. DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. Hepatol Commun 2021;5:1448-59. [PMID: 34430788 DOI: 10.1002/hep4.1730] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Pitcairn CFM, Kawka M. Contrast-enhanced ultrasonography for intrahepatic cholangiocarcinoma: A cost-effective alternative for low-resource settings. Hepatobiliary Pancreat Dis Int 2021;20:304-5. [PMID: 33349606 DOI: 10.1016/j.hbpd.2020.12.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Ledenko M, Patel T. What are the key challenges in the pharmacological management of cholangiocarcinoma? Expert Opin Pharmacother 2021;:1-3. [PMID: 34866539 DOI: 10.1080/14656566.2021.2010707] [Reference Citation Analysis]
163 Hozaka Y, Seki N, Tanaka T, Asai S, Moriya S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, Kurahara H, Ohtsuka T. Molecular Pathogenesis and Regulation of the miR-29-3p-Family: Involvement of ITGA6 and ITGB1 in Intra-Hepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:2804. [PMID: 34199886 DOI: 10.3390/cancers13112804] [Reference Citation Analysis]
164 Rodrigues PM, Vogel A, Arrese M, Balderramo DC, Valle JW, Banales JM. Next-Generation Biomarkers for Cholangiocarcinoma. Cancers (Basel) 2021;13:3222. [PMID: 34203269 DOI: 10.3390/cancers13133222] [Reference Citation Analysis]
165 Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:343-50. [PMID: 33645367 DOI: 10.1080/13543784.2021.1897102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
166 Gerber TS, Bartsch F, Wagner DC, Schindeldecker M, Heuft LK, Roth W, Lang H, Straub BK. Clinicopathological Significance of Syndecan-1 in Cholangiocarcinoma: A Study Based on Immunohistochemistry and Public Sequencing Data. J Clin Med 2021;10:2745. [PMID: 34206469 DOI: 10.3390/jcm10132745] [Reference Citation Analysis]
167 Cadamuro M, Lasagni A, Lamarca A, Fouassier L, Guido M, Sarcognato S, Gringeri E, Cillo U, Strazzabosco M, Marin JJ, Banales JM, Fabris L. Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. Expert Opin Investig Drugs 2021;30:377-88. [PMID: 33622120 DOI: 10.1080/13543784.2021.1880564] [Reference Citation Analysis]
168 Yin L, Zhao S, Zhu H, Ji G, Zhang X. Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study. Sci Rep 2021;11:12166. [PMID: 34108604 DOI: 10.1038/s41598-021-91823-x] [Reference Citation Analysis]
169 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Rizzo A, Dadduzio V, Lombardi L, Ricci AD, Gadaleta-Caldarola G. Ampullary Carcinoma: An Overview of a Rare Entity and Discussion of Current and Future Therapeutic Challenges. Curr Oncol 2021;28:3393-402. [PMID: 34590592 DOI: 10.3390/curroncol28050293] [Reference Citation Analysis]
171 Ruffolo LI, Jackson KM, Kuhlers PC, Dale BS, Figueroa Guilliani NM, Ullman NA, Burchard PR, Qin SS, Juviler PG, Keilson JM, Morrison AB, Georger M, Jewell R, Calvi LM, Nywening TM, O'Dell MR, Hezel AF, De Las Casas L, Lesinski GB, Yeh JJ, Hernandez-Alejandro R, Belt BA, Linehan DC. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut 2021:gutjnl-2021-324109. [PMID: 34413131 DOI: 10.1136/gutjnl-2021-324109] [Reference Citation Analysis]
172 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
173 Guest RV. Targeted therapies in cholangiocarcinoma: emerging hope through novel trial design. Br J Surg 2021:znab410. [PMID: 34875028 DOI: 10.1093/bjs/znab410] [Reference Citation Analysis]
174 Kawasaki K, Kuboki S, Furukawa K, Takayashiki T, Takano S, Ohtsuka M. LGR5 induces β-catenin activation and augments tumour progression by activating STAT3 in human intrahepatic cholangiocarcinoma. Liver Int 2021;41:865-81. [PMID: 33249719 DOI: 10.1111/liv.14747] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Mohr R, Özdirik B, Knorr J, Wree A, Demir M, Tacke F, Roderburg C. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease? Int J Mol Sci 2020;21:E4993. [PMID: 32679791 DOI: 10.3390/ijms21144993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
176 Liu H, Lin L, Lin Z, Chen Y, Huang Q, Ding L, Lou J, Zheng S, Bi X, Wang J, Guo W, Li F, Wang J, Zheng Y, Li J, Cheng S, Zhou W, Cheng Z, Zeng Y. Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study. BMC Cancer 2021;21:840. [PMID: 34284743 DOI: 10.1186/s12885-021-08560-7] [Reference Citation Analysis]
177 Kajioka H, Muraoka A. Rapid recurrence of spindle cell type undifferentiated carcinoma early after radical surgery in a bile duct cancer patient - A case report. Int J Surg Case Rep 2021;81:105800. [PMID: 33756162 DOI: 10.1016/j.ijscr.2021.105800] [Reference Citation Analysis]
178 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Reference Citation Analysis]
179 Renzulli M, Ramai D, Singh J, Sinha S, Brandi N, Ierardi AM, Albertini E, Sacco R, Facciorusso A, Golfieri R. Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. Cancers (Basel) 2021;13:3336. [PMID: 34283065 DOI: 10.3390/cancers13133336] [Reference Citation Analysis]
180 Nguyen Canh H, Takahashi K, Yamamura M, Li Z, Sato Y, Yoshimura K, Kozaka K, Tanaka M, Nakanuma Y, Harada K. Diversity in cell differentiation, histology, phenotype and vasculature of mass-forming intrahepatic cholangiocarcinomas. Histopathology 2021. [PMID: 34018212 DOI: 10.1111/his.14417] [Reference Citation Analysis]
181 Kimawaha P, Jusakul A, Junsawang P, Thanan R, Titapun A, Khuntikeo N, Techasen A. Establishment of a Potential Serum Biomarker Panel for the Diagnosis and Prognosis of Cholangiocarcinoma Using Decision Tree Algorithms. Diagnostics (Basel) 2021;11:589. [PMID: 33806004 DOI: 10.3390/diagnostics11040589] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep 2021;3:100226. [PMID: 33665585 DOI: 10.1016/j.jhepr.2021.100226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
183 Ilyas FZ, Beane JD, Pawlik TM. The State of Immunotherapy in Hepatobiliary Cancers. Cells 2021;10:2096. [PMID: 34440865 DOI: 10.3390/cells10082096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Rizzo A, Ricci AD, Brandi G. Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. Expert Review of Precision Medicine and Drug Development 2021;6:225-7. [DOI: 10.1080/23808993.2021.1910023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Waddell SH, Boulter L. Developing models of cholangiocarcinoma to close the translational gap in cancer research. Expert Opin Investig Drugs 2021;30:439-50. [PMID: 33513027 DOI: 10.1080/13543784.2021.1882993] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
186 Klinhom-On N, Seubwai W, Sawanyawisuth K, Obchoei S, Mahalapbutr P, Wongkham S. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sci 2021;286:120072. [PMID: 34688691 DOI: 10.1016/j.lfs.2021.120072] [Reference Citation Analysis]
187 Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol 2021. [PMID: 34131315 DOI: 10.1038/s41571-021-00521-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
188 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Reference Citation Analysis]
189 Noguchi D, Kuriyama N, Nakagawa Y, Maeda K, Shinkai T, Gyoten K, Hayasaki A, Fujii T, Iizawa Y, Tanemura A, Murata Y, Kishiwada M, Sakurai H, Mizuno S. The prognostic impact of lymphocyte-to-C-reactive protein score in patients undergoing surgical resection for intrahepatic cholangiocarcinoma: A comparative study of major representative inflammatory / immunonutritional markers. PLoS One 2021;16:e0245946. [PMID: 33507925 DOI: 10.1371/journal.pone.0245946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
190 Chang YC, Chen MH, Yeh CN, Hsiao M. Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. Biomolecules 2020;10:E1377. [PMID: 32998289 DOI: 10.3390/biom10101377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Manzia TM, Parente A, Lenci I, Sensi B, Milana M, Gazia C, Signorello A, Angelico R, Grassi G, Tisone G, Baiocchi L. Moving forward in the treatment of cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(12): 1939-1955 [DOI: 10.4251/wjgo.v13.i12.1939] [Reference Citation Analysis]
192 Wang SQ, Chai CX, Wang BR, Zhu F, Shang D, Li M. Liquid biopsy: Precise diagnosis and therapy for cholangiocarcinoma. World J Gastrointest Oncol 2022; 14(1): 362-365 [DOI: 10.4251/wjgo.v14.i1.362] [Reference Citation Analysis]
193 Roy S, Jefferys D, Rubbo S, Mayo-Ramsay T, Majid A. Anatomical reconstruction after pancreaticoduodenectomy in a patient with previous Roux-en-Y gastric bypass for obesity: a novel complication for the future. ANZ J Surg 2021. [PMID: 34820991 DOI: 10.1111/ans.17379] [Reference Citation Analysis]
194 Bahra M. [Surgical treatment of distal cholangiocarcinoma]. Chirurg 2021;92:788-95. [PMID: 34232340 DOI: 10.1007/s00104-021-01453-2] [Reference Citation Analysis]
195 Hu J, Wang YN, Song DJ, Tan JP, Cao Y, Fan J, Wang Z, Zhou J. A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. Diagnostics (Basel) 2021;11:610. [PMID: 33805513 DOI: 10.3390/diagnostics11040610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
196 Rizzo A, Brandi G. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. Expert Review of Gastroenterology & Hepatology 2021;15:547-54. [DOI: 10.1080/17474124.2021.1890031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
197 Mariotti V, Fiorotto R, Cadamuro M, Fabris L, Strazzabosco M. New insights on the role of vascular endothelial growth factor in biliary pathophysiology. JHEP Rep 2021;3:100251. [PMID: 34151244 DOI: 10.1016/j.jhepr.2021.100251] [Reference Citation Analysis]
198 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities? Expert Rev Gastroenterol Hepatol 2021;15:1239-40. [PMID: 34449276 DOI: 10.1080/17474124.2021.1974296] [Reference Citation Analysis]
199 Carpino G, Cardinale V, Di Giamberardino A, Overi D, Donsante S, Colasanti T, Amato G, Mennini G, Franchitto M, Conti F, Rossi M, Riminucci M, Gaudio E, Alvaro D, Mancone C. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma. J Hepatol 2021:S0168-8278(21)01947-4. [PMID: 34329660 DOI: 10.1016/j.jhep.2021.07.016] [Reference Citation Analysis]
200 Komuta M. Histological Heterogeneity of Primary Liver Cancers: Clinical Relevance, Diagnostic Pitfalls and the Pathologist's Role. Cancers (Basel) 2021;13:2871. [PMID: 34201284 DOI: 10.3390/cancers13122871] [Reference Citation Analysis]
201 Wang Y, Li K, Zhao W, Liu Z, Liu J, Shi A, Chen T, Mu W, Xu Y, Pan C, Zhang Z. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression. Cell Death Dis 2021;12:1158. [PMID: 34907179 DOI: 10.1038/s41419-021-04451-8] [Reference Citation Analysis]
202 Lin Z, Gong J, Zhong G, Hu J, Cai D, Zhao L, Zhao Z. Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma. Front Oncol 2021;11:666847. [PMID: 34055632 DOI: 10.3389/fonc.2021.666847] [Reference Citation Analysis]
203 Luo X, Campbell NA, He L, O'Brien DR, Singer MS, Lemjabbar-Alaoui H, Ahn KS, Smoot R, Torbenson MS, Rosen SD, Roberts LR. Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis. Hepatology 2021. [PMID: 33735525 DOI: 10.1002/hep.31817] [Reference Citation Analysis]
204 Gou Q, Zhang CZ, Sun ZH, Wu LG, Chen Y, Mo ZQ, Mai QC, He J, Zhou ZX, Shi F, Cui W, Zou W, Lv L, Zhuang WH, Xu RD, Li WK, Zhang J, Du HW, Xiang JX, Wang HZ, Hou T, Li ST, Li Y, Chen XM, Zhou ZJ. Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer. ESMO Open 2021;6:100275. [PMID: 34653800 DOI: 10.1016/j.esmoop.2021.100275] [Reference Citation Analysis]
205 Kim-Fuchs C, Candinas D, Lachenmayer A. The Role of Conventional and Stereotactic Microwave Ablation for Intrahepatic Cholangiocarcinoma. J Clin Med 2021;10:2963. [PMID: 34279447 DOI: 10.3390/jcm10132963] [Reference Citation Analysis]
206 Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer 2021;1876:188638. [PMID: 34688805 DOI: 10.1016/j.bbcan.2021.188638] [Reference Citation Analysis]
207 Vithayathil M, Bridegwater J, Khan SA. Medical therapies for intra-hepatic cholangiocarcinoma. J Hepatol 2021;75:981-3. [PMID: 34215442 DOI: 10.1016/j.jhep.2021.04.004] [Reference Citation Analysis]
208 Fabris L, Andersen JB, Fouassier L. Intrahepatic cholangiocarcinoma: A single-cell resolution unraveling the complexity of the tumor microenvironment. J Hepatol 2020;73:1007-9. [PMID: 32900521 DOI: 10.1016/j.jhep.2020.07.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
209 Songjang W, Nensat C, Pongcharoen S, Jiraviriyakul A. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomed Rep 2021;15:86. [PMID: 34512974 DOI: 10.3892/br.2021.1462] [Reference Citation Analysis]
210 Wang Q, Xu Y, Wang SM, Hu AY, Pan YC, Zhang SH. Histopathological evidence of intrahepatic cholangiocarcinoma occurring in ductal plate malformation: A clinicopathologic study of 5 cases. Ann Diagn Pathol 2021;55:151828. [PMID: 34571341 DOI: 10.1016/j.anndiagpath.2021.151828] [Reference Citation Analysis]
211 van Keulen AM, Franssen S, van der Geest LG, de Boer MT, Coenraad M, van Driel LMJW, Erdmann JI, Haj Mohammad N, Heij L, Klümpen HJ, Tjwa E, Valkenburg-van Iersel L, Verheij J, Groot Koerkamp B, Olthof PB; Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG). Nationwide treatment and outcomes of perihilar cholangiocarcinoma. Liver Int 2021;41:1945-53. [PMID: 33641214 DOI: 10.1111/liv.14856] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
212 Liang J, Zhou H, Huang XQ, Liu YF, Zhang L, He D, Cui Y, Guo J, Hu K, Wu C. A Myeloid Signature-Based Nomogram Predicts the Postoperative Recurrence of Intrahepatic Cholangiocarcinoma. Front Mol Biosci 2021;8:742953. [PMID: 34722632 DOI: 10.3389/fmolb.2021.742953] [Reference Citation Analysis]
213 Meadows V, Francis H. Doublecortin-Like Kinase Protein 1 in Cholangiocarcinoma: Is This the Biomarker and Target We Have Been Looking For? Hepatology 2021;73:4-6. [PMID: 33179783 DOI: 10.1002/hep.31630] [Reference Citation Analysis]
214 Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, Melisi D, Macarulla T, Ueno M, Kim ST, Meyers O, Workman C, Bachini M, Cohen G. Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study. Oncol Ther 2021. [PMID: 34244955 DOI: 10.1007/s40487-021-00159-z] [Reference Citation Analysis]
215 Sinniah RS, Shapses MS, Ahmed MU, Babiker H, Chandana SR. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. Expert Opin Investig Drugs 2021;30:1047-56. [PMID: 34579607 DOI: 10.1080/13543784.2021.1985461] [Reference Citation Analysis]
216 Cho MT, Gholami S, Gui D, Tejaswi SL, Fananapazir G, Abi-jaoudeh N, Jutric Z, Samarasena JB, Li X, Valerin JB, Mercer J, Dayyani F. Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary Approach. Cancers 2022;14:392. [DOI: 10.3390/cancers14020392] [Reference Citation Analysis]
217 Dong L, Lu D, Chen R, Lin Y, Zhu H, Zhang Z, Cai S, Cui P, Song G, Rao D, Yi X, Wu Y, Song N, Liu F, Zou Y, Zhang S, Zhang X, Wang X, Qiu S, Zhou J, Wang S, Zhang X, Shi Y, Figeys D, Ding L, Wang P, Zhang B, Rodriguez H, Gao Q, Gao D, Zhou H, Fan J. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 2021:S1535-6108(21)00659-0. [PMID: 34971568 DOI: 10.1016/j.ccell.2021.12.006] [Reference Citation Analysis]
218 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Reference Citation Analysis]
219 Janthamala S, Jusakul A, Kongpetch S, Kimawaha P, Klanrit P, Loilome W, Namwat N, Techasen A. Arctigenin inhibits cholangiocarcinoma progression by regulating cell migration and cell viability via the N-cadherin and apoptosis pathway. Naunyn Schmiedebergs Arch Pharmacol 2021. [PMID: 34283274 DOI: 10.1007/s00210-021-02123-0] [Reference Citation Analysis]
220 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. Toward personalized therapy for cholangiocarcinoma: new insights and challenges. Expert Rev Gastroenterol Hepatol 2021;15:1241-3. [PMID: 34553646 DOI: 10.1080/17474124.2021.1984879] [Reference Citation Analysis]
221 Chiow SM, Khoo HW, Low JK, Tan CH, Low HM. Imaging mimickers of cholangiocarcinoma: a pictorial review. Abdom Radiol. [DOI: 10.1007/s00261-021-03399-9] [Reference Citation Analysis]
222 Casolino R, Braconi C. CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma. J Hepatol 2021;74:1021-4. [PMID: 33612309 DOI: 10.1016/j.jhep.2021.01.030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Padthaisong S, Phetcharaburanin J, Klanrit P, Li JV, Namwat N, Khuntikeo N, Titapun A, Jarearnrat A, Wangwiwatsin A, Mahalapbutr P, Loilome W. Integration of global metabolomics and lipidomics approaches reveals the molecular mechanisms and the potential biomarkers for postoperative recurrence in early-stage cholangiocarcinoma. Cancer Metab 2021;9:30. [PMID: 34348794 DOI: 10.1186/s40170-021-00266-5] [Reference Citation Analysis]
224 Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs 2021;30:429-38. [PMID: 33322977 DOI: 10.1080/13543784.2021.1865308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Arechederra M, Rullán M, Amat I, Oyon D, Zabalza L, Elizalde M, Latasa MU, Mercado MR, Ruiz-Clavijo D, Saldaña C, Fernández-Urién I, Carrascosa J, Jusué V, Guerrero-Setas D, Zazpe C, González-Borja I, Sangro B, Herranz JM, Purroy A, Gil I, Nelson LJ, Vila JJ, Krawczyk M, Zieniewicz K, Patkowski W, Milkiewicz P, Cubero FJ, Alkorta-Aranburu G, G Fernandez-Barrena M, Urman JM, Berasain C, Avila MA. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures. Gut 2021:gutjnl-2021-325178. [PMID: 34285068 DOI: 10.1136/gutjnl-2021-325178] [Reference Citation Analysis]
226 Peng Y, Meng G, Sheng X, Gao H. Transcriptome and DNA methylation analysis reveals molecular mechanisms underlying intrahepatic cholangiocarcinoma progression. J Cell Mol Med 2021. [PMID: 34013637 DOI: 10.1111/jcmm.16615] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
227 Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, Wu C, Chakraborty S, Glaser S, Alpini G. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs 2021;30:365-75. [PMID: 33226854 DOI: 10.1080/13543784.2021.1854725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
228 Xiang X, Liu Z, Zhang C, Li Z, Gao J, Zhang C, Cao Q, Cheng J, Liu H, Chen D, Cheng Q, Zhang N, Xue R, Bai F, Zhu J. IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma. Adv Sci (Weinh) 2021;:e2101230. [PMID: 34250753 DOI: 10.1002/advs.202101230] [Reference Citation Analysis]
229 Marušić M, Paić M, Knobloch M, Vodanović M. Klatskin-Mimicking Lesions. Diagnostics (Basel) 2021;11:1944. [PMID: 34829291 DOI: 10.3390/diagnostics11111944] [Reference Citation Analysis]
230 Cigliano A, Chen X, Calvisi DF. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Expert Rev Gastroenterol Hepatol 2021;15:511-26. [PMID: 33888034 DOI: 10.1080/17474124.2021.1915128] [Reference Citation Analysis]
231 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
232 Angelico R, Sensi B, Parente A, Siragusa L, Gazia C, Tisone G, Manzia TM. Vascular Involvements in Cholangiocarcinoma: Tips and Tricks. Cancers (Basel) 2021;13:3735. [PMID: 34359635 DOI: 10.3390/cancers13153735] [Reference Citation Analysis]
233 Ness JR, Molvar C. Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies. Semin Intervent Radiol 2021;38:438-44. [PMID: 34629711 DOI: 10.1055/s-0041-1735526] [Reference Citation Analysis]
234 Zori AG, Yang D, Draganov PV, Cabrera R. Advances in the management of cholangiocarcinoma. World J Hepatol 2021; 13(9): 1003-1018 [PMID: 34630871 DOI: 10.4254/wjh.v13.i9.1003] [Reference Citation Analysis]
235 Liu J, Ren G, Li K, Liu Z, Wang Y, Chen T, Mu W, Yang X, Li X, Shi A, Zhao W, Xu B, Chang J, Guo S, Pan C, Zhou T, Zhang Z, Xu Y. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma. Cell Death Differ 2021. [PMID: 34799729 DOI: 10.1038/s41418-021-00897-7] [Reference Citation Analysis]
236 Bourien H, Lamarca A, McNamara MG, Hubner RA, Valle JW, Edeline J. Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opin Investig Drugs 2021;30:975-83. [PMID: 34420429 DOI: 10.1080/13543784.2021.1964470] [Reference Citation Analysis]
237 Nanashima A, Komi M, Imamura N, Yazaki S, Hiyoshi M, Hamada T, Yano K, Nishida T, Enzaki M, Sakae T. Novel analysis using magnetic resonance cholangiography for patients with pancreaticobiliary maljunction. Surg Today 2021. [PMID: 34324090 DOI: 10.1007/s00595-021-02349-8] [Reference Citation Analysis]
238 Titapun A, Luvira V, Srisuk T, Jareanrat A, Thanasukarn V, Thanee M, Sa-Ngiamwibool P, Padthaisong S, Duangkumpha K, Suksawat M, Loilome W, Sithithaworn P, Techasen A, Thinkhamrop B, Dzienny A, Caglayan A, Park D, Mahmud S, Khuntikeo N. High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection. Int J Gen Med 2021;14:2191-204. [PMID: 34103974 DOI: 10.2147/IJGM.S306339] [Reference Citation Analysis]